1403387-30-3

Upstream product

• 1433497-80-3 1-(3-bromo-5-tert-butylphenyl)ethanol 
• 241155-85-1 3-bromo-5-formyl-tert-butylbenzene 
• 129316-09-2 1,3-dibromo-5-t-butylbenzene 
• 67-64-1 acetone 
• 1124138-68-6 1-(3-bromo-5-(tert-butyl)phenyl)ethanone 
• 75-16-1 methylmagnesium bromide 

Downstream Products

• 1403387-32-5 2-(3-bromo-5-(tert-butyl)phenyl)-2-methylpropanal 
• 1403387-33-6 2-(3-bromo-5-(tert-butyl)phenyl)-2-methylpropan-1-ol 
• 1403387-34-7 1-bromo-3-(tert-butyl)-5-(1-fluoro-2-methylpropan-2-yl)benzene 
• 1346640-69-4 1-bromo-3-tert-butyl-5-isopropylbenzene 
• 1433497-82-5 (3-tert-butyl-5-isopropyl-phenyl)boronic acid 
• 1442430-98-9 1-bromo-3-(tert-butyl)-5-(2-methoxypropan-2-yl)benzene 
• 1442430-99-0 2-(3-(tert-butyl)-5-(2-methoxypropan-2-yl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 

Relevant academic research and scientific papers

SUBSTITUTED PYRAZOLE ANALOGUES AS RAR ANTAGONISTS

The present invention provides compounds of Formula I or a pharmaceutical salt thereof; methods of treating osteoarthritis and the pain associated with osteoarthritis using the compounds; and processes for preparing the compounds.

PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORGAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES

The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administrating these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo sulfonamide compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.